Cargando…

Interleukin‐33 as an early predictor of cetuximab treatment efficacy in patients with colorectal cancer

BACKGROUND: Cetuximab is used for colorectal cancer (CRC) treatment. However, the early biomarker of treatment efficacy of cetuximab has not been identified. METHODS: After 1 year of cetuximab treatment, patients were divided into an effective group and an ineffective group. The interleukin‐33 (IL‐3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xujun, Bi, Kefan, Tu, Xiaoxuan, Zhang, Qiong, Cao, Qingyi, Liang, Yan, Zeng, Ping, Wang, Lin, Liu, Tianxing, Fang, Weijia, Diao, Hongyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633246/ https://www.ncbi.nlm.nih.gov/pubmed/34664425 http://dx.doi.org/10.1002/cam4.4331

Ejemplares similares

The Contradictory Role of Interleukin-33 in Immune Cells and Tumor Immunity
por: Zhang, Xujun, et al.
Publicado: (2020)

MicroRNAs Regulate Intestinal Immunity and Gut Microbiota for Gastrointestinal Health: A Comprehensive Review
por: Bi, Kefan, et al.
Publicado: (2020)

In-depth characterization of the biomarkers based on tumor-infiltrated immune cells reveals implications for diagnosis and prognosis in hepatocellular carcinoma
por: Chen, Wenbiao, et al.
Publicado: (2020)

RBM15-mediated N6-methyladenosine modification affects COVID-19 severity by regulating the expression of multitarget genes
por: Meng, Yuting, et al.
Publicado: (2021)

Influenza A virus NS1 protein hijacks YAP/TAZ to suppress TLR3-mediated innate immune response
por: Zhang, Qiong, et al.
Publicado: (2022)

Long noncoding RNA and mRNA profiling in cetuximab‐resistant colorectal cancer cells by RNA sequencing analysis
por: Jing, Changwen, et al.
Publicado: (2019)

Comprehensive Study of Tumor Immune Microenvironment and Relevant Genes in Hepatocellular Carcinoma Identifies Potential Prognostic Significance
por: Chen, Wenbiao, et al.
Publicado: (2020)

First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
por: Zhou, Yu‐Wen, et al.
Publicado: (2021)

Hepatitis B virus P protein initiates glycolytic bypass in HBV-related hepatocellular carcinoma via a FOXO3/miRNA-30b-5p/MINPP1 axis
por: Chen, Wenbiao, et al.
Publicado: (2021)

Phospholipid metabolites of the gut microbiota promote hypoxia-induced intestinal injury via CD1d-dependent γδ T cells
por: Li, Yuyu, et al.
Publicado: (2022)

Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial
por: Lipsyc-Sharf, Marla, et al.
Publicado: (2022)

Fc‐gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer
por: Shepshelovich, Daniel, et al.
Publicado: (2018)

Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis
por: Parikh, Aparna R, et al.
Publicado: (2022)

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer
por: Sobrero, Alberto, et al.
Publicado: (2020)

Up-regulated microRNA-33b inhibits epithelial–mesenchymal transition in gallbladder cancer through down-regulating CROCC
por: Xu, Guohui, et al.
Publicado: (2020)

CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab
por: Skougaard, Kristin, et al.
Publicado: (2014)

Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status
por: Kato, Junko, et al.
Publicado: (2016)

Osteopontin Exacerbates High-Fat Diet-Induced Metabolic Disorders in a Microbiome-Dependent Manner
por: Chen, Jianing, et al.
Publicado: (2022)

p16, HPV, and Cetuximab: What Is the Evidence?
por: Bonner, James A., et al.
Publicado: (2017)

Colorectal cancer (CRC) as a multifactorial disease and its causal correlations with multiple signaling pathways
por: Wan, Mao-lin, et al.
Publicado: (2020)

Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)
por: Hatch, Ace J., et al.
Publicado: (2016)

lncRNA-HEIM Facilitated Liver Fibrosis by Up-Regulating TGF-β Expression in Long-Term Outcome of Chronic Hepatitis B
por: Yao, Jian, et al.
Publicado: (2021)

A High-Salt Diet Exacerbates Liver Fibrosis through Enterococcus-Dependent Macrophage Activation
por: Zhang, Xujun, et al.
Publicado: (2023)

Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
por: Chan, Wing-Lok, et al.
Publicado: (2014)

Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer
por: Hsu, Hung‐Chih, et al.
Publicado: (2019)

Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in KRAS wild‐type metastatic colorectal cancer patients: the ObservEr Study
por: Pinto, Carmine, et al.
Publicado: (2016)

A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF (V600E)-Mutant KRAS Wild-Type Metastatic Colorectal Cancer
por: Tabernero, Josep, et al.
Publicado: (2023)

MiRNA-574-3p inhibits cell progression by directly targeting CCND2 in colorectal cancer
por: Li, Wen-Cui, et al.
Publicado: (2019)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer
por: Leto, Simonetta M., et al.
Publicado: (2023)

LncRNA TUG1 promotes the progression of colorectal cancer via the miR-138-5p/ZEB2 axis
por: Yan, Zhenkun, et al.
Publicado: (2020)

Commentary on: Screening of immunosuppressive cells from colorectal adenocarcinoma and identification of prognostic markers
por: Chen, Kexin, et al.
Publicado: (2021)

Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance
por: Torlot, Lucien, et al.
Publicado: (2022)

Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAF(V600E)-Mutant Colorectal Cancer
por: Napolitano, Stefania, et al.
Publicado: (2023)

A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions
por: Maier, Sabine, et al.
Publicado: (2015)

Predictors of interleukin-33 and thymic stromal lymphopoietin levels in cord blood
por: Ashley-Martin, Jillian, et al.
Publicado: (2015)

Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer
por: Cruz-Duarte, Raquel, et al.
Publicado: (2022)

Anemia of inflammation in patients with colorectal cancer: Correlation with interleukin-1, interleukin-33 and galectin-1
por: Jocić, Miodrag, et al.
Publicado: (2022)

PRSS contributes to cetuximab resistance in colorectal cancer
por: Tan, Zhaoli, et al.
Publicado: (2020)

Pretreatment serum interleukin‐1β, interleukin‐6, and tumor necrosis factor‐α levels predict the progression of colorectal cancer
por: Chang, Pei‐Hung, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_enohn7kbpgm87vuc2hmjg8cvpj